There is a new strain of HIV that has an atypical enzyme
structure. As such, none of the current inhibitors are effective
against the HIV protease [Essential Biochemistry (p206, 3rd
edition); (p198, 4th edition)]. You are charged with developing a
new inhibitor for this new HIV strain with different protease.
1. Describe how you can design an inhibitor for this HIV
2. How can you test the inhibitor for biologic effect?